Leukemia therapeutics companies focus on the research, development, and commercialization of treatments for leukemia, a type of cancer that affects the blood and bone marrow. Therapies for leukemia may include chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation.
Latest Leukemia Therapeutics Companies Update
July 2023: New favorable Phase III data on the subcutaneous formulation of Leqembi (lecanemab-irmb) have been released by BioArctic and Eisai. At the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts, the firms presented the data. An open-label extension (OLE) substudy of the Clarity AD trial, the Phase III trial (NCT03887455) evaluated intravenous infusion (IV) and subcutaneous (SC) dosing of Leqembi. Compared to biweekly IV delivery, data showed that weekly SC injection of the medication reduced amyloid plaques by 14% at six months, as determined by positron emission tomography (PET).Â
Oct 2023: An interim review of a late-stage treatment trial revealed that Novartis' investigational drug atrasentan improved an indication of kidney health in patients with a rare kind of kidney disease. Compared to a placebo, treatment with the therapeutic candidate—acquired as part of the acquisition of the U.S. biotech company Chinook for up to $3.5 billion—produced a significant improvement in proteinuria in patients with IgA nephropathy, the Swiss drugmaker stated. Excess protein in the urine is known as proteinuria, which may indicate a problem with the kidneys' ability to filter waste. In addition, Novartis stated that it intends to discuss the interim data with the US Food and Drug Administration to pursue expedited approval. Novartis is developing two more medication options to treat IgAN. The trial will go forward, and the business stated that additional kidney function read-outs are anticipated in the first quarter of 2026.
Leukemia Therapeutics Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)